Request Demo
Last update 26 Feb 2026
Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)
Last update 26 Feb 2026
Overview
Basic Info
Drug Type Personalized antigen vaccine |
Synonyms- |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)NCT05098210
PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer, PD1/PD-L1 Inhibitor-Refractory Melanoma, and Pretreated Non-Small Cell Lung Cancer
100 Clinical Results associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)
Login to view more data
100 Translational Medicine associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)
Login to view more data
100 Patents (Medical) associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)
Login to view more data
100 Deals associated with Neoantigen Peptide Vaccine(Fred Hutchinson Cancer Research Center)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hormone Receptor Positive Breast Adenocarcinoma | Phase 1 | United States | 09 Jun 2022 | |
| Hormone receptor positive HER2 negative breast cancer | Phase 1 | United States | 09 Jun 2022 | |
| Locally Advanced Melanoma | Phase 1 | United States | 09 Jun 2022 | |
| Malignant melanoma of conjunctiva | Phase 1 | United States | 09 Jun 2022 | |
| Melanoma recurrent | Phase 1 | United States | 09 Jun 2022 | |
| Metastatic breast cancer | Phase 1 | United States | 09 Jun 2022 | |
| Metastatic melanoma | Phase 1 | United States | 09 Jun 2022 | |
| metastatic non-small cell lung cancer | Phase 1 | United States | 09 Jun 2022 | |
| Metastatic Solid Tumor | Phase 1 | United States | 09 Jun 2022 | |
| Recurrent HER2-Negative Breast Carcinoma | Phase 1 | United States | 09 Jun 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free